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CHAPTER 1 
INTRODUCTION 
1.1 BACKGROUND1,2,3 
      The possible explanations to relate the Gall stone disease with 
Hypothyroidism are: 
1) Disturbance of lipid metabolism in hypothyroidism causes increase 
in serum cholesterol level which leads to supersaturation of bile 
with cholesterol. It leads to change in composition of bile and 
formation of cholesterol stones. 
2) Recent studies demonstrated low bile flow in hypothyroid patients. 
It leads to stagnation of bile in gall bladder and it allows more time 
for nucleation process for gall stone formation. 
3) Sphincter of oddi has thyroid hormone receptors and thyroxine has 
direct prorelaxing effect on the sphincter smooth muscle cell. 
4) In hypothyroidism, the effect of UDP glucuronyl transferase get 
decreased. So the conjugation of bilirubin gets affected. Increase in 
unconjugated bilirubin result in formation of pigment stones. 
5) In animal model (Rabbits), thyroxine usage dissolves the fatty diet 
induced gall stones.3 
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1.2 AIM: 
The aims of this study are 
1) To study the prevalence of hypothyroidism in patients diagnosed 
with cholelithiasis/ choledocholithiasis. 
2) To assess if thyroid profile is warranted in patients with biliary stone 
disease. 
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CHAPTER 2 
REVIEW OF LITERATURE 
2.1 EMBRYOLOGY 4,5,6,7: 
     The gall bladder, bile ducts and liver begins to develop during 4th 
week of embryonic life as a ventral bud from the most caudal aspect of 
foregut. This bud is called hepatic diverticulum, and it grows between 
the layers of ventral mesentery.  
      The hepatic diverticulum has 2 components: pars hepatica and pars 
cystica. 
       Pars hepatica is the most cranial component , gives rise to liver, 
intra hepatic bile ducts and common hepatic duct.  
       Pars cystica is the most caudal component, gives rise to cystic 
diverticulum. The cystic diverticulum is the analge of gall bladder and 
cystic duct. 
      The original hepatic diverticulum elongates to form common bile 
duct.  
       These structures begins as solid cords. Establishment of lumen 
throughout the biliary tract occurs at 8 week of gestation.  
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2.2 GROSS ANATOMY: 
       The gall bladder is a thin walled, slate-blue colored, sac like, globular 
or pear shaped hollow viscus organ with a capacity of about 50ml. It 
measures about 7.5cm to12.5cm in length and 3cm in breadth at its widest 
part. It lies in a fossa in the right lobe of  liver on its visceral surface just 
adjacent to the caudate lobe. It is attached to liver by a loose areolar tissue, 
rich in small blood vessels and lymphatics. The extra hepatic portion of the 
gallbladder is covered by peritoneum. Fewer than 10% of the gallbladder is 
covered by peritoneum and is attached to the liver by a narrow mesentery 
from the undersurface of liver. 
      The gallbladder typically lies in close proximity to duodenum, pylorus, 
hepatic flexure of right colon and right kidney. Its anatomical subdivisions 
are fundus, body and neck that terminates in a narrow infundibulum. 
Fundus is the rounded, blind portion of gallbladder that extends for a short 
distance beyond the sharp lower border of liver. It is directed downwards, 
forwards and to the right to occupy a cystic notch in the margin of  liver. 
When the gall bladder is full, the fundus comes in contact with the parietal 
peritoneal layer of the anterior abdominal wall  just behind the right 9th 
costal cartilage where the transpyloric plane crosses the right costal 
margin, at the lateral border of right rectus sheath. The fundus of gall 
bladder lies just to the left of  hepatic flexure. It is generally the least well 
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vascularised portion of the gallbladder and therefore is more susceptible to 
ischemic changes, including perforation. 
          The body constitutes the majority of gallbladder, directed upwards 
and backwards and to the left towards the right end of porta hepatis. It is in 
relation by its upper surface with the liver; by its undersurface with the 
right part of transverse colon and further back with the superior part of 
duodenum and the upper end of the descending part. 
          The neck is a narrow portion of the upper end of  gallbladder that 
lies between the body and cystic duct region.  It curves upwards and 
forwards, and then turning abruptly backwards and downwards, becomes 
continuous with cystic duct. When the liver is in normal position, the neck 
of gall bladder lies at a higher level than its fundus and against the free 
edge of lesser omentum. At its point of continuity with cystic duct there is 
a constriction. The neck is attached to the liver by a areolar tissue in which 
the cystic artery is embeded. 
           The infundibulum is a small bulbous diverticulum of gall bladder, 
typically lying on the inferior surface of the right wall of neck of the 
gallbladder, and it projects downwards and backwards towards the 
duodenum. This is often termed as Hartmann’s pouch has been widely 
regarded as a constant feature of normal gallbladder.  
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  The cystic duct is a tubular structure, which connects the gall bladder to 
common bile duct. It is a continuation of the neck and is 2cm to 3cm in 
length and 2mm to 3mm in diameter. It passes downwards, backwards and 
to the left from the neck of gallbladder towards the porta hepatis. It joins 
with the common hepatic duct between the two layers of peritoneum, that 
forms the free edge of the lesser omentum about 1cm above the duodenum 
and anterior to the right hepatic artery and its cystic branch. Cystic duct 
runs parallel to common hepatic duct for a short distance and adheres  with 
it. 
Fig 1: overall arrangement of intrahepatic and extra hepatic biliary tree 
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Calot’s triangle is the space bounded by cystic duct inferiorly; common 
hepatic artery medially; cystic artery superiorly. This was described by 
Jean francois calot in 1891. It is a surgical landmark while doing 
cholecystectomy to avoid damage to the extra hepatic biliary system 
 
            The common bile duct, about 7.5cm in length and it is formed by 
the union of cystic and common hepatic ducts. It lies within the hepato 
duodenal ligament, to the right of the hepatic artery and anterior to the 
portal vein. It is divided into four parts. The supraduodenal portion, about 
2.5cm in length, runs in the free edge of lesser omentum. The retro 
                     Fig 2: Anatomical variations of cystic duct 
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duodenal portion lies behind the second part of duodenum. The infra 
duodenal portion lies in a groove on the neck of pancreas. The intra 
duodenal portion passes obliquely through the wall of second part of the 
duodenum and opens into the duodenum on the summit of papilla of vater. 
This structure surrounds the orifice of bile duct and is composed of 
duodenal tissue and muscular elements which makes the sphincter of oddi. 
Typically, there is a common channel, which both the pancreatic and distal 
common bile duct joining, which opens through single orifice into the 
duodenum. This common channel is believed to be quite important in the 
pathogenesis of gall stone pancreatitis. 
2.3 HISTOLOGY: 
           Histologically the gall bladder consists of three distinct layers:  
serosal, fibromuscular and mucosal layer. The serosal layer is derived from 
peritoneum and it completely invests the fundus, but covers only the 
inferior surface and sides of the body and neck of gall bladder. Beneath it 
has subserosal layer of areolar tissue. The fibromuscular layer is a thin 
layer of fibrous tissue, mixed with nonstriated muscular fibres; these are in 
loose bundles disposed in longitudinal, circular and oblique directions; 
arranged in a criss cross manner, being particularly well developed in the 
neck. The mucosal layer is loosely connected with the fibromuscular layer. 
This layer contains indentations of the mucosa that sink into the muscle 
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coat, these are called crypts of Luschka. The epithelium consists of a single 
layer of columnar cells. The mucosa in neck secrete mucus but mainly it 
has absorptive function. 
            In the cystic duct, the mucosa is elevated into 5 to 12 cresentric 
folds, called as, “Valves of Heister”. They appear to play an important role 
in the passage of bile into and out of gall bladder. Microscopically the 
layers of bile duct appear similar to that of gall bladder. The outer 
fibromuscular layer has strong connective tissue fibers with scant muscular 
elements, its density increases in the more distal segments of the duct. The 
mucosa is composed of a single layer of columnar epithelium. Electron 
microscopic studies have demonstrated the presence of microvilli and cilia 
in the apical membrane of the ductal cells. These structures are thought to 
be important in the mixing and motor activities of the duct. 
 
                      Fig 3: Histology of gall bladder 
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2.4 ARTERIAL SUPPLY: 
         The major blood supply of the gall bladder is through the cystic 
artery, which is typically a branch of right hepatic artery. The gall bladder 
also receives many small vessels from its hepatic bed. Branches from 
cystic artery supplies the common bile duct (upper part) and hepatic duct. 
The lower part of the bile duct receives branches from the posterior 
superior pancreatico-duodenal artery. The right hepatic artery gives 
branches to the middle part of the bile duct. 
 
 
  
Fig 4: Normal anatomy of cystic artery 
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2.5 VENOUS DRAINAGE: 
          The veins draining the gall bladder vary considerably. Those from its 
upper surface lies in the areolar tissue between the gallbladder and liver 
and it runs directly into the liver through the fossa of gallbladder to join 
with the hepatic veins. Those from the rest of the gall bladder join to form 
one or more cystic veins on its neck, and these commonly enter into liver, 
either directly or after joining with the veins draining the hepatic ducts and 
upper part of the bile duct.  
 
2.6 LYMPHATIC DRAINAGE: 
            The lymphatics draining the gall bladder tend to be more important 
for both inflammatory and malignant disease of gall bladder. The 
lymphatic channels from the subserosal and submucosal plexus drain into 
cystic lymph node of Lund- the sentinel lymph node, which lies in the fork 
created by the junction of cystic duct and common hepatic ducts and to a 
node situated at the anterior border of epiploic foramen. Efferent vessels 
from these nodes pass through the free edge of lesser omentum to the 
celiac group of preaortic nodes. The subserosal lymphatic vessels of the 
gall bladder have connection with the subcapsular lymphatic channels of 
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liver, and it accounts for the frequent spread of carcinoma of gallbladder to 
the liver. 
2.7 NERVE SUPPLY: 
          The wall of the gall bladder is richly innervated by both sympathetic 
and parasympathetic nerve fibers, which pass along the hepatic artery and 
its branches. Parasympathetic fibers, mainly from the hepatic branch of 
anterior vagal trunk, stimulates contraction of the gall bladder and relaxes 
the ampullary sphincter. Sympathetic fibers from the celiac ganglia, with 
the preganglionic cells in the lateral horn of the spinal cord segments, T7-
T9 inhibits contraction of gall bladder. Autonomic plexus of the nerve lies 
in the muscular and sub mucosal layers. Fibers from the right phrenic 
nerve, through communication between phrenic and celiac plexus, appear 
to reach the gallbladder via hepatic plexus explaining the referred 
“shoulder pain” in the gall bladder pathology.  
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2.8 PHYSIOLOGY OF GALL BLADDER 7,8,9: 
               The primary function of gall bladder is to concentrate the bile by 
absorption of water and sodium to acquire the greater strength and 
digestive power. The gallbladder and bile ducts are well adopted for the 
function of storing and secreting bile into the duodenum during digestion. 
The flow of bile in and out of the gallbladder is determined by contraction 
and relaxation of the sphincter of Oddi. The normal gallbladder is rarely 
static. Continuous cycles of partial emptying and refilling is governed by 
the intestinal migratory myoelectric complex between meals. During 
relaxation and refilling it intermittently contracts and expels pulses of bile 
into the duodenum. This constant fluctuation prevents formation of stone. 
Gallbladder tone is modulated by both vagus and circulating peptides. 
During cephalic phase of digestion stimulation of vagus is responsible for 
gallbladder contraction. During interdigestive period, the vagal neurons 
and circulating polypeptides mediates the contraction. Vasoactive 
intestinal polypeptide [VIP] released by vagal neurons inhibits gallbladder 
contraction and mediates post prandial filling of gall bladder. Its motility 
gets inhibited by truncal vagotomy and by chronic fasting. 
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2.9 BIOCHEMISTRY OF BILE: 
         Bile as it leaves the liver is composed of 97% of water, 1 to 2% of 
bile salts, 1% of bile pigments, cholesterol and fatty acids. The knowledge 
of the chemistry of the constituents of bile is essential as they have a great 
importance in the etiology of cholelithiasis. 
Bile acids and bile salts:  The bile acids of the human bile are glycocholic 
acid and taurocholic acids which are conjugated products of glycine and 
cystine with cholic acid respectively. Bile acids are present in bile as bile 
salts in the form of sodium glycocholate and sodium taurocholate. Human 
bile consists approximately 70 to 75% glycocholate and 25% of 
taurocholate. 
Bile pigments: The biliary pigments are bilirubin and biliverdin. .Bilirubin 
is the chief pigment in the human bile. Biliverdin is the exudative product 
of bilirubin and is present in small quantity in human bile. The pigment 
forms about 15 to 20% of total solids in liver bile. They are derived mainly 
from hemoglobin and a small amount from chromoprotiens. 
Lipids: The normal bile contains fatty acids, cholesterol and 
phospholipids. Cholesterol normally occurs to the extent of 0.04 to 0.16% 
in liver bile. It is present in the free state and its concentration is more in 
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gall bladder bile. Normally the ratio between the cholesterol and bile salts 
varies between 1:20 to 1:30. 
Mucin: Its main constituent is mucealbumin. It increases in obstructive 
and inflammatory conditions of the biliary tract pathology and it forms the 
cementing substance in gall stones. 
TABLE 1: COMPOSITION OF BILE 
 LIVER BILE GALL BLADDER 
BILE 
Water 97.5g/dl 92g/dl 
Bile salts 1.1g/dl 6g/dl 
Cholesterol 0.1g/dl 0.3 to 0.9 g/dl 
Bilirubin 0.04g/dl 0.3g/dl 
Fatty acids 0.12g/dl 0.3 to 1.2g/dl 
Lecithin 0.04g/dl 0.3g/dl 
K+ 5mEq/L 12mEq/L 
Na+ 145.04 mEq/L 130mEq/L 
Cl- 100mEq/L 25mEq/L 
Ca++ 5mEq/L 23mEq/L 
HCO3- 28mEq/L 10mEq/L 
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2.10 Entero Hepatic Circulation:    
      Following normal fatty meal, emulsification of cleavage products from 
triglyceride hydrolysis by pancreatic lipase results in the incorporation of 
fat molecules into micelles.  Absorption of fat takes primarily in the upper 
small intestine, whereas  bile acids undergo little absorption until the distal 
third of the small intestine is reached. In the ileum, there exists specific 
high affinity binding sites for the active absorption of bile acids.  Due to 
the efficiency of this absorptive process, less than 5% of daily excreted 
bile reaches the large bowel.  Upon absorption, bile acids enters the portal 
vein and return to liver.  This 95% return rate of bile acids to the liver has 
two consequences. First, most of the bile acids excreted through bile are 
actively recycled rather than newly synthesized. Second bile acids exert a 
feed back inhibition that regulates estrogen, cholesterol, and fat soluable 
vitamins. 
2.11 FUNCTIONS OF THE GALLBLADDER: 
1. Reservoir of bile: During the intercibal period, the sphincter of Oddi is 
closed and the bile excreted by the liver is directed to the gallbladder. After 
food, the resistance to flow through sphincter of Oddi is reduced, the 
gallbladder contracts and bile enters the duodenum. Narcotic drugs such as 
morphine and pethedine increases sphincter tone , whereas anticholenergic  
and  glyceryl trinitrate decrease the tone. 
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2. Concentration of bile:  By active absorption of sodium, water, chloride, 
bicarbonate by the gall bladder into the bloodstream and to a lesser extent 
into the lymphatics, the liver bile which enters the gallbladder becomes 
concentrated 5 to 10 times with a corresponding increase in the proportion 
of bile pigments, bile salts, cholesterol and calcium it contains. In disease, 
the gallbladder instead of absorbing fluids pours fluids rapidly. The 
absorption of the bile salts gets enhanced while more of calcium and 
cholesterol is seen in the lumen. Here lies the relationship between 
inflammation of the gall bladder and the stone formation. It is said that the 
desquamated epithelium forms the nucleus of the gall stone, the increased 
amount of calcium and cholesterol crystals forms the raw material, while 
the increased absorption of bile salts results in the precipitation of 
cholesterol molecules. 
3. Secretion of the mucus: The gallbladder secretes 20ml of thick viscid 
mucus per day. Allegedly this mucus protects the mucosa from the lytic 
action of the bile and facilitates the flow of thick bile through the cystic 
duct. The colourless fluid found in the hydrops of the gallbladder and the 
so called white bile found in choledochal obstruction, severe cholangitis 
and toxic hepatitis is not bile at all but is a mucinous  secretion containing  
calcium carbonate with no bile salts and  bile pigments.  
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4. Excretion of cholesterol:  The presence of cholesterol esters in the 
layers of the gallbladder in the pathological entity like strawberry 
gallbladder or cholesteroses of gallbladder led some physiologists to 
ascribe the function of excretion of cholesterol molecules by gallbladder. 
Others say that diffuse collection of cholesterol in the layers of gallbladder 
is an evidence of abnormal absorption of lipid molecules.  Thus there has 
been much difference of opinion as to whether cholesterol is absorbed or 
excreted. 
5.  Pressure regulation: Gallbladder equalizes the pressure difference 
within the biliary tract by virtue of its power of absorption of bile. This is 
brought about by the fact that the quantity of bile secreted in 24hours is 
about 20 times or greater than could be stored in the gallbladder. The less 
of its action in equalizing the pressure within the biliary duct system is 
probably leading to the dilatation of the biliary ducts, which so frequently 
follows cholecystectomy. 
6.  Change in the reaction of bile:  The hepatic bile is distinctly alkaline 
with a pH of 7.1 to 8.5 whereas bile that reaches the duodenum is almost 
neutral with a pH of 5.5 to7.7. This is due to bicarbonate ions being 
reabsorbed by gallbladder. 
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2.12 GALL STONES: 
       The basis for classification of gall stone has generally been related to 
stone composition or structure, because analysis of these gall stone 
characteristics are simple.  
The broadest classification of stones is into 3 categories 10 
1.   Cholesterol  
2.   Pigment 
3.   Mixed. 
RISK FACTORS FOR GALLSTONES 13 
o Risk increases with age 
o Obesity 
o Female sex 
o Race and Ethnicity 
o Heredity 
o Parity 
o Rapid Weight Loss 
o Medications: Estrogens, Oral contraceptives, Clofibrate and 
octreotide 
o Cystic fibrosis 
o Intravenous Hyper alimentation 
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o Cirrhosis 
o Hemolysis 
o Diabetes Mellitus 
o Vagotomy 
o Hyperlipidemia 
 
CHOLESTEROL STONE PATHOGENESIS: 
          The distinction between the cholesterol and pigment types can be 
made by inspection of a stone and chemically13. It also has the merits of 
distinguishing those gallstones which should respond to medical 
dissolution therapy (cholesterol gallstone) and those that will not. 
Biliary vesicles, nonmicellar carriers of cholesterol on bile: 
         Vesicles which are unilamellar spherical structures made of 
cholesterol crystals, phospholipids and little if any bile salts are 
substantially larger than simple micelles or mixed micelles but much 
smaller than layered crystals. Vesicles which are relatively stable in 
dilute bile such as hepatic bile and when the concentration of bile salts 
are relatively low. Transformation of vesicles to mixed micelles occurs 
in the lumen of gallbladder with high bile salt concentration. If the 
cholesterol to phospholipids ratio is less than 1:2 then they are 
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relatively stable and if the ratio raises above 1 then vesicles become 
insoluble and fuse to form a larger multi lamellar vesicles called liquid 
crystals. These liquid crystals are inherently unstable and form a solid 
cholesterol monohydrate crystals. 
15
So these vesicles will serve as the 
primary source of cholesterol during nucleation. 
CHOLESTEROL SATURATION OF BILE: 
        1. The most common mechanism is increased cholesterol secretion 
with normal bile salt and phospholipids secretion and this mechanism 
occurs in obese patients and many non obese patients. 
        2. Decreased secretion of bile salts coupled with normal 
secretion of cholesterol occurs in patients with ileal resection. 
        3. Both excess secretion of cholesterol and decreased secretion of bile 
salts. 
 
Excessive cholesterol secretion may be due to. 
  An increase in the activity of rate limiting enzyme HMG Co-A 
reductase.  
Decrease in cholesterol esterification or inhibition of cholesterol acyl 
transferase                                                                                                                              
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   Decrease  in the activity  of 7 alpha-hydroxylase  rate  limiting  enzyme  
for  synthesis  of primary  bile salts   
     Increased lipoprotein uptake by the lumen with OCP use 
CHOLESTEROL SOLUBILITY IN BILE: 
             The relative proportions of cholesterol, bile salts, phospholipids in 
the bile are important in determining the maximal solubility of cholesterol. 
The degree of saturation of bile with cholesterol can be quantified by  
Cholesterol saturation index CSI or lithogenic index. At the boundary of 
micellar zone, bile is saturated and CSI is 1.00 or 100% supersaturated bile 
has a CSI of above 1.00 and unsaturated bile a CSI below 1.00. Patients 
with cholesterol gallstones were thought to have bile composition that fell 
outside the micellar zone on triangular phase diagrams and normal patients 
have bile composition within the zone. 
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FIG 5A: BILIARY CHOLESTEROL CARRIERS 
FIG 5B: BILIARY CHOLESTEROL SATURATION 
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NUCLEATION: 
      Nucleation of solid cholesterol monohydrate crystals form a 
supersaturated bile. Nucleating and anti nucleating factors may influence 
this process at one or more points.  
Nucleating factors: 
           Glycoprotein nucleating factor with an apparent molecular mass of 
130 Kda  that binds to conanavalin 16 
         Gallbladder mucin: Mucin can promote nucleation in a model bile 
system.17 
Antinucleating factors: 
     Apolipoprotein A-I and A-II could prolong the nucleation time of 
supersaturated bile. 
    Influence of gallbladder concentration: Nucleation time is shorter in 
patients with cholesterol stones with well concentrated bile. 
Morphology of Cholesterol Stones: 
        Cholesterol stones constitute more than 80% of gall stones in the western 
world. They are mainly composed of crystals of the cholesterol molecules. 
25 
 
Stones can be almost pure cholesterol and contain cholesterol monohydrate 
crystals agglomerated by a mucin glycolprotein matrix. Minor components of 
cholesterol stones contains unconjugated bilirubin and small quantity of 
calcium phosphate 11. Cholesterol stones are light brown in colour, smooth or 
faceted, single or multiple and on cross section show a laminated and or 
crystalline appearance12. Cholesterol gall stones may be diagnosed when they 
are small in size and on cholecystography or ultrasonography demonstrates 
the floating stones with some shadowing without internal echoes. Calcium 
salts form the nidus in the center of the stone. They may also be dispersed 
rather evenly throughout the stone or in a lamellar fashion or ring like 
distribution throughout the periphery13. 
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PATHOGENESIS OF BLACK PIGMENT GALL STONES: 
      Factors associated with pathogenesis of black gall stones are10 
                  Chronic liver disease 
                   Ileal resection 
                   Chronic hemolysis  
         FIG 6  MORPHOLOGY OF GALL STONES 
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                   Total parenteral nutrition 
                   Vagotomy 
   Black pigment stones are made of insoluble polymer of calcium 
bilirubinate. Bile  is sterile and unconjugated bilirubin may be formed 
because of increased bilirubin in bile as a consequence of above mentioned 
causes . Other factors included are excess of calcium in bile or stasis and 
glycoprotein secretion18, acidification defect- possibly as a result of 
inflammation, or by the buffering capacity of  sialic acid and sulfate 
moieties of the mucus gel. The buffering effect facilitates the super 
saturation of calcium carbonate and phosphate.12 
         Increased  production of unconjugated bilirubin can result from 
increased production of bilirubin which occurs in hemolysis or alcoholism 
and is associated with  black pigment gall stone formation. Conditions that 
increase the colonic bile salt concentration such as ileal disease have been 
hypothesized to favour the resorption of unconjugated bilirubin and 
subsequent hypersecretion into bile.  
  PATHOGENISIS OF BROWN PIGMENT STONE: 
      Brown pigment stones are usually found in common bile duct. Stasis 
and infection are invariably present. Enzymes such as glucuronidase, 
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phospholipase  and deconjugase  plays a role in forming insoluble salts 
such as calcium bilirubinate, calcium palmitate and calcium stearate as 
well as reducing cholesterol carrying capacity of bile. 
       Brown stones have 20% to 80% cholesterol by weight. (30% contributed 
by mucin glycoprotein made of bacterial glycocalyx.)18 
Morphology of Pigment stones: 
      Pigment stones consist primarily of pigments (either calcium bilirubinate 
or pigment polymers) and other calcium salts 
Pigment stones have 2 major sub sets 
1.         Black 
2.         Brown. 
     Black pigment gall stones contain primarily of calcium bilirubinate or 
pigment polymers and calcium carbonate may also be present , along with 
mucin10. Black pigment stones contain calcium salts of unconjugated bilirubin 
in a polymerized matrix. The additional presence of calcium phosphate 
molecule in the mucin matrix results in opacity of black pigment stones on 
plain radiographs13. 
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      Brown pigment gall stones also consist primarily of calcium bilirubinate 
but have little if any calcium carbonate or phosphate. They contain substantial 
amounts of calcium salts of fatty acids, usually Palmitic acid, and also 
contains some amounts of cholesterol10. The hallmark of brown pigment 
stones is the presence of bacterial degradation products of biliary lipids, 
calcium salts of fatty acids and unconjugated billirubin14. 
TABLE 2: DIFFERENCE BETWEEN BLACK AND BROWN PIGMENT 
STONE 
BLACK PIGMENT STONE BROWN PIGMENT STONE 
Shiny black Dull brown 
Made of Polymers of calcium 
bilirubinate 
Made of crystalline or amorphous 
calcium bilirubinate 
Resist manual crushing Laminated and soft 
Found in gallbladder Found in bile ducts 
Bile is sterile Bile is infected 
Contains a trace of calcium palmitate, 
calcium carbonate and  calcium 
phosphate 
Contains 15% calcium palmitate and 
or stearate and traces of calcium 
carbonate or calcium phosphate 
Contains less than 20% cholesterol 
 
Cholesterol 
Contains 20% – 80% cholesterol 
 
Cholesterol 
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Morphology of Mixed stone: 
         These are stones that contain cholesterol monohydrate crystals along 
with varying degree of calcium components  i.e. calcium carbonate, 
phosphate, bilirubinate, or palmitate. Most of the mixed stones are 
multifaceted with angular edge. A shiny greenish black colour predominates. 
Cut surface shows a concentric laminated structure due to rhythmical 
deposition of biliary constituents including cholesterol, bile pigments and 
calcium. When mixed stones are lobulated they are sometimes called as 
mulberry stones. 
IMAGING STUDIES OF THE BILIARY TRACT10 : 
       Only 50% of pigment stones and 20% of cholesterol stones 
contain enough calcium to be visible on a plain abdominal film. Plain 
abdominal films have greatest utility in evaluating complications of 
gallstones such as emphysematous cholecystitis, Cholecysto-enteric 
fistula and a porcelain gallbladder. 
 Ultrasonography: Principal imaging modality for the diagnosis 
of cholelithiasis Should follow a fast of atleast 8hrs because 
gallstones are best seen in a distended bile filled gallbladder. 
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Diagnosis relies on the findings of echogenic objects within the lumen of 
gallbladder that produces an acoustic shadow19. Can detect stones as small 
as 2mm in size with sensitivity greater than 95% and specificity greater 
than 95% when stones are seen with accompanying acoustic shadow. The 
contracted gallbladder filled with stones may give a “double arc shadow” 
or “ wall echo shadow” sign. Distinctly less powerful for detection of 
stones in CBD 
CT Abdomen: Less sensitive than USG abdomen .  Main advantage is to 
study the status of extrahepatic biliary tree and adjacent structures. Used 
to identify CBD stones and dilatation of CBD and other biliary radicles in 
obstructive jaundice cases. 
   . 
 
        Fig 7 : ultrasound abdomen showing multiple stones in lumen of gall bladder 
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Fig 8: multiple gall stones in plain xray abdomen showing radio opaque shadow 
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ERCP: Is the gold standard investigation for the diagnosis of 
choledocholithiasis with sensitivity greater than 95%. With contrast 
medium flowing retrograde into the gallbladder, stones  appear as filling 
defects detectable with sensitivity of 80%. 
 
 
 
 
 
 
Fig 9 : ERCP- showing side endoscope picture in duodenum 
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Oral Cholecystography: Limited application as a secondary 
means of identifying stones in the gallbladder20. 
 
 
 
 
 
 
 
 
Fig 10: oral cholecystography showing smoth filling defect in  the cystic duct 
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CT Cholangiography and MRCP: These investigations are 
helpful in detecting complications of gallstones such as 
pericholecystic fluid in acute cholecystitis, gas in the gallbladder 
wall in emphysematous Cholecystitis, and gallbladder perforation. 
 
 
CLINICAL MANIFESTATION AND COMPLICATIONS OF 
GALLSTONE DISEASE:12 
                         1.   Asymptomatic stones 
Fig11: MRCP- Shows the course of extra hepatic biliary tree 
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                         2.   Stone intermittently obstructing cystic duct  causing 
intermittent  biliary colic 20%. 
                         3.   Stone impacted in cystic duct causing acute 
cholecystitis 10%. 
                     4.   Stone in cystic duct  compressing or fistulising into 
common bile  duct causing  Mirrizzi syndrome < 0.1%. 
                     5.   Stone impacted in distal common bile duct causing 
jaundice, biliary colic type of pain and risk of ascending cholangitis or 
acute biliary pancreatitis 5%. 
                     6.   Stone eroding through the gallbladder into duodenum, 
resulting in cholecystoenteric fistula. 
                     7.   Long standing cholelithiasis resulting in gallbladder  
                     8.   Emphysematous  cholecystitis  –secondary infection of   
gall bladder wall with gas forming organisms. 
                     9.   Porcelain gall bladder: intramural calcification of gall 
bladder wall, usually associated with stones can lead to gall bladder 
carcinoma in approximately 20% 
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ELECTIVE TREATMENT OF GALLBLADDER STONES: 
                       The choices for elective therapy of gallstones have 
expanded in the last several decades. Cholecystectomy is the treatment of 
choice for symptomatic gallstones and includes both traditional open and 
laparoscopic approaches. For patients who are reluctant to undergo 
surgery or who are at high surgical risk, oral bile salt therapy, usually 
with Ursodiol is an option provided the patients have some radiolucent 
stones in a functioning gallbladder. Elective percutaneous radiological 
extraction of stones from the gallbladder is rarely performed but it is an 
another option.10 
                         Extracorporeal shock wave lithotripsy [ESWL] combined 
with bile salts is being utilized. It is most successful in patients with 
single radiolucent stones although it is also used for patients with more 
than one stone. Percutaneous instillation of solvents, particularly methyl 
tert-butyl ether [MTBE], into gallbladder lumen is being investigated 
because of its safety and efficacy and appears to be most useful for 
patients with radiolucent stones of any size or number. 
BILE SALT THERAPY 
           The most widely used non surgical treatment for stones in the 
gallbladder is administration of an oral bile salt, either Chenodiol or 
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Ursodiol. Ursodiol is used far more extensively than Chenodiol. The 
combination of both is sometimes used for Bile salt therapy is a 
potential alternative to cholecystectomy for patients at high operative 
risk. However the use of bile salt need not be limited to such high risk 
patients. Others may benefit from bile salt therapy, such as those who 
wish to avoid surgery or those whose symptoms are exceedingly mild. 
Dissolution of gallstones with Chenodiol:21 
               Chenodiol (chenodeoxycholic acid) was the first bile salt 
reported to dissolve gallstones. Chenodiol is a dihydroxy bile salt that 
normally accounts for about one third of the human bile salt pool. 
Administration of chenodiol in sufficient doses results in secretion of 
hepatic bile that is unsaturated with cholesterol. Unsaturated hepatic bile 
enters the gallbladder, where it can bathe the surface of gallstones. 
Miscelles in unsaturated bile can absorb cholesterol from the surface of 
cholesterol gallstones, gradually diminishing their size and eventually, 
under optimal circumstances, completely dissolving them. Chenodiol 
did not achieve any degree of widespread use and is rarely used as 
monotherapy. Its major drawbacks are dose related side effects. The two 
most common are diarrhoea and elevation of serum amino transferase 
levels. Chenodiol is occasionally used in combination with Ursodiol for 
gallstone dissolution [usually at the dosage of 5-7.5 mg/kg/day each] 
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Dissolution of gallstones with Ursodiol:21 
            Ursodiol is a naturally occurring dihydroxy bile salt that 
accounts for approximately 1% to 2% of the total human bile salt 
pool. The safety and ease of administration of Ursodiol make it 
the first non surgical option to consider when an alternative to 
cholecystectomy is sought. Ursodiol has been used most 
extensively as monotherapy for dissolution of cholesterol 
gallstones but has also been increasingly used after fragmentation 
of gallstones by ESWL. Ursodiol dissolves gallstones by 
solubilizing cholesterol from the surface of the stones. Ursodiol 
administration results in the conversion of bile supersaturated 
with cholesterol to unsaturated bile. In addition to desaturation, it 
has the unique property of promoting the formation of a liquid 
crystal mesophase [phospholipids plus cholesterol] in bile. 
Chenodiol does not do so. Liquid crystals can form in the 
presence of bile that is saturated with cholesterol. Liquid crystals 
are less dense than bile and are expelled from the gallbladder as it 
empties. The proportion of Ursodiol in the bile rises maximally 
during therapy to 55% to 60% and levels off there after 2 weeks, 
even with higher doses.The optimal dosage of Ursodiol is 8 to 
10mg/kg/day. A strict linear relationship does not exist between 
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the dose and complete stone dissolution. Doses as low as 3 to 
5mg/kg/day have resulted in stone dissolution. Doses above 
10mg/kg/day do not result in higher dissolution rate. 
EXTRA CORPOREAL SHOCKWAVE LITHOTRIPSY: 
         Use of ESWL for the treatment of the gallstones followed its 
successful application for kidney stones. A major impetus for the 
development of gallstone lithotripsy was the limited success of gallstone 
dissolution using the bile salts ursodiol and chenodiol, which may require 
2 years or more and has an overall success rate of about 30 %. 
         Fragmentation of gallstones into small particles can aid in 
overcoming problems of big stones by increasing the surface area /volume 
ratio and disrupting localized areas of calcium salts. Shockwaves that are 
used in lithotripsy are complex acoustic waves that typically have a single 
pressure spike of sharp upstroke with gradual relaxation. The amplitude of 
shockwaves used therapeutically is in the range of 600 to 1000 bars. 
         The finer the fragmentation of stone, the more effectively the 
fragments can be dissolved by bile salts or emptied by the gallbladder. 
Optimal fragment size after ESWL is 3mm or less. Fragmentation of 
multiple gallstones is less successful than that of single stone.  The two 
potential mechanisms for gallstone fragments clearance are gallbladder 
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emptying of fragments and dissolution by oral bile salt therapy. 
Fragments may be rapidly cleared through gallbladder emptying in a few 
patients. However, dissolution of fragments by oral bile salt therapy is the 
principle mechanism for their disappearance in the majority of patients. 
          Symptomatic patients with a patent cystic duct are the most 
important prerequisites. Single radiolucent stones 20mm or less in 
diameter are optimal for ESWL therapy. Fragment clearance is directly 
proportional to initial gallstone number and size. Best results are for one 
stone of 20mm or less, and approximately 50% to 70% of such patients 
become stone free after 6 months. 
         Complications of ESWL include hematuria, skin petechiae or 
ecchymoses and asymptomatic elevation of serum aminotransferase or 
amylase values in some patients. Delayed problems include transient 
mild biliary pain, presumably as a result of fragment passage, occurring 
in 30% to 50% of patients within 6 to 12 months after ESWL. Serious 
complications occur infrequently and include pancreatitis and common 
bile duct obstruction. 
CONTACT DISSOLUTION THERAPY:10 
          Infusion of a chemical agent directly into the gallbladder or bile 
ducts in an attempt to dissolve gallstones is known as contact dissolution 
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therapy. Solvents can be delivered through indwelling T-tube catheters, 
percutaneous transhepatic biliary tube, nasobiliary catheters or 
percutaneous cholecystostomy tubes. Commonly used dissolution agents 
are monoctanoin and methyl tert-butyl ether. 
SURGICAL THERAPY:22 
        Cholecystectomy has become most common general surgical 
procedure now. Around 650,000 cholecystectomies are performed 
annually in the USA. 
Indications for the cholecystectomy include 
             Biliary colic 
             Acute cholecystitis 
             Chronic cholecystitis 
             Complications of gall stone disease 
             Asymptomatic gallstones larger than 2cms 
OPEN CHOLECYSTECTOMY: 
     Open cholecystectomy carries an overall mortality of around 0.17% 
with mortality rates for patients under and over 65yrs of age being 
0.03% and 0.5% respectively . 
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         Technique:  Open cholecystectomy is typically performed 
through a right sub costal incision 2-3cms below the right costal margin. 
Satisfactory access can also be gained through a midline laparotomy 
incision. Two techniques are available for open cholecystectomy 
             Ante grade  method (fundus first method) 
             Retrograde method  
          Retrograde cholecystectomy begins with dissection in the Calot’s 
triangle to identify the cystic duct as it enters the infundibulum of 
gallbladder. Once identified the cystic duct is mobilised and divided and 
cystic duct stump is suture ligated. Cystic artery is similarly identified 
and ligated. If  the Calot’s triangle demonstrates considerable edema 
and inflammation in the presence of acute cholecystitis, ante grade 
cholecystectomy is generally safer and advocated to minimize the 
chances of inadvertent CBD or hepatic duct injury. 
      Ante grade cholecystectomy starts at the fundus, dividing the 
peritoneal attachments of the gallbladder to the liver and mobilizing the 
gallbladder from the gallbladder fossa. Once identified the cystic duct is 
mobilised and divided and cystic duct stump is suture ligated. Cystic 
artery is similarly identified and ligated. 
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LAPAROSCOPIC CHOLECYSTECTOMY: 
          Although laparoscopic cholecystectomy first reported in 1988, it 
has rapidly become the standard of care in many parts of the world for 
patients with gallstone disease. The key to laparoscopic cholecystectomy 
is to create a satisfactory pneumoperitoneum and expose the triangle of 
calot. Thereafter the principles of safe cholecystectomy are the same as 
those used for open retrograde cholecystectomy. The cystic duct and 
artery must be clearly visualized. Anatomic variation in the position of 
ductal and arterial structures must be sought to avoid ductal injury and 
vascular compromise. 
FIG 12: LAPAROSCOPIC AND OPEN CHOLECTSTECTOMY 
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The indications for laparoscopic choliangiography include                                              
          CBD dilatation 
          History of jaundice 
          Hyper amylasemia 
          Abnormal liver function tests 
          Palpable duct stones 
    Indications to convert to open cholecystectomy: 
          Inability to identify key anatomical structures 
          Marked inflammations with adhesions to adjacent viscera 
          Hemorrhage 
          Bile duct injury 
          Discovery  of unexpected pathology 
Common Bile Duct Exploration: 
                   Common bile duct stones that are detected intraoperatively on 
intraoperative cholangiography or ultrasonography may be managed with 
laparoscopic choledochal exploration as a part of the laparoscopic 
cholecystectomy procedure. Patients with common bile duct stones 
detected preoperatively, but in whom endoscopic clearance was either not 
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available or unsuccessful, should also have their ductal stones managed 
during the cholecystectomy. If the stones in the duct are small, they may 
sometimes be flushed into the duodenum with saline irrigation via the 
cholangiography catheter after the sphincter of Oddi has been relaxed with 
glucagon. When the duct has been cleared, the cystic duct is ligated and 
cut and the cholecystectomy completed. Occasionally, a choledochotomy, 
an incision into the common bile duct itself, is necessary. The flexible 
choledochoscope is then passed into the duct for visualization and 
clearance of stones. The choledochotomy is sutured with a T tube left in 
the common bile duct with one end taken out through the abdominal wall 
for decompression of the bile ducts. By managing common bile duct 
stones at the time of the cholecystectomy, the patients can have all of their 
gallstone disease treated with one invasive procedure. It does, however 
depend on the available surgical expertise. 
2.13 THYROID HORMONES: 
PHYSIOLOGY OF THYROID METABOLISM:23,24,25,26,27,28 
          Thyroid function is closely related to the iodine metabolism because 
the hormones produced by the thyroid gland-thyroxine and tri-
iodothyronine contain high proportion of iodine. The effect of these two 
hormones are qualitatively very similar  but  differ  dramatically  in  their  
time  and  course  of  action.  Thyroid hormones play an important role in 
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the regulation of growth, brain development, and for maintaining 
metabolism and functional activity of most organs. 
Iodine metabolism: 
                   The normal thyroid gland contains approximately 5000-8000 
µg of iodine, only about 1 percent being inorganic iodide. The normal 
daily intake of iodine in food and water is about 150 µg. All iodine is 
converted into iodide in the gut and in this form, it is completely and 
rapidly absorbed into the blood.  
Synthesis of thyroid hormones: 
               Left: TSH binds its receptor and promotes thyroid hormone 
production. Circulating I- is taken up at the basolateral membrane via 
the sodium-iodide symporter, NIS. Intracellular I- accumulates and 
moves across the apical membrane by a process believed at least 
partially to be mediated by Pendrin, thereby providing this essential 
element for hormone synthesis.       
  Middle: Tg is produced by the thyroid epithelial cells, 
processed along the synthetic pathway and released into the follicular 
lumen. 
 Top: H2O2, required for the coupling of I- and Tg, is generated 
by DUOX2 at the apical membrane. 
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 Reaction of these components is catalysed by TPO; I- is 
coupled to many tyrosine residues within Tg, of which only a select 
number are   hormonogenic. Tyrosine residues can be either mono- or 
di-iodinated. TPO also facilitates  coupling  of  these  residues  to  
form  precursor  to  T3  (mono-  + di-iodinated) and T4 (2 × di-
iodinated). 
  Right: Outline of endocytosis and processing of the pro-
hormone. Some Tg is proteolysed at the apical surface by externalized 
cathepsins prior to uptake Internalized Tg is proteolysed by cathepsins 
within lysosomes.T3 and T4 exit basolaterally in a process at least 
partially mediated by MCT8, a monocarboxylic acid transporter of the 
SLC16 family . Un-utilized iodotyrosines are further degraded by 
iodotyrosine dehalogenases and recycled.25 
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FIG 13: SYNTHESIS OF THYROID HORMONES 
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Storage: After synthesis, the thyroid hormones are stored in 
thyroglobulin. Each molecule of thyroglobulin contains one to three 
molecules of thyroxine, and an average of one tri-iodothyronine 
molecule for every 14 molecules of thyroxine. In this form the thyroid 
hormones are often stored in the follicles for several months. Release 
of T4 and T3 
The thyroid gland is unique within the endocrine system in 
having a large extracellular space, the follicular lumen used for 
storage of the hormones and their precursors. The thyroid is unique 
among the endocrine glands by virtue of the large store of hormones 
that it contains and the slow-rate at which the hormone is released. 
In the thyroid gland, the organic iodine is constituted as 
follows, T4 constitutes approximately 35 per cent, T3 – 5 percent and 
iodothyrosines (DIT & MIT) about 60 per cent. 
The apical surface of thyroid cells send pseudopodia like 
extensions around the colloid. The proteinases present in the 
lysosomal enzymes digest the thyroglobulin molecules to release T3 
and T4 which diffuse through the basement membrane into the blood. 
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Transportation, turnover and metabolism of thyroid hormone: 
       In the blood, T4 and T3 are almost entirely bound to plasma 
proteins such as thyroxine binding globulin (TBG), thyroxine binding 
pre-albumin (TBPA) and thyroxine binding albumin (TBA). Normally 
99.98% of the T4 in the plasma is protein bound. The free T4 level is 
only above 2ng/dL. There is very little T4 in the urine. Of the 0.15 
g/dL of normally found T3 in plasma, 0.2% (0.3 ng/dL) is    free. The 
remaining 99.8% is protein bound. Homeostatic regulation of thyroid 
function is directed towards the maintenance of free thyroxine rather 
than total hormone concentration. Half-life of thyroxine (T4) is 6 days 
and T3 has a half life of 1-3 days. 
The thyroid gland has a storage reserve of approximately three 
weeks. TBG molecular weight – 60,000D with a half life of about 5 
days. It has a high affinity but low capacity for T4 – which is 2-6 
times greater than for T3. TBPA molecular weight 50,000D with half 
life of about 2 days. Can bind much T4 and little T3. Albumin has low 
affinity but high capacity for T4 and T3 binding. 
The function of protein binding of thyroid hormones may be to 
help, to reduce the proportion of free hormones in the blood which 
inturn reduces loss by kidney and liver maintaining the plasma level 
of free hormones T4 is more firmly bound to plasma proteins so it  is  
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more stable than T3 in the body. T4 is  a extracellular hormone, while 
T3 penetrates tissue fluids and cells rapidly. T3 is quicker acting and 
more potent than T4. T4 is very largely converted to T3 by 
deiodination – so, it acts as a prohormone. 
There are several routes of T4 metabolism, the major route (85 
percent) is deiodination to T3 (monodeiodination at 5’ position) or to 
reverse T3 (monodeiodination at the 5 position) in the liver, kidney 
and other sites. Other routes include conjugation to form glucuronides 
and sulphates and alteration of alanine side chain to form acetic or 
propionic acid. 
PHYSIOLOGICAL    EFFECTS     OF     THYROID     
HORMONES     ON DIFFERENT BODILY MECHANISMS 
       The principal effects of thyroid hormone is to increase the metabolic 
effects of most tissues of the body (with few exceptions such as brain, 
retina, spleen, testes and lungs). The growth rate of young persons is 
greatly increased. Many specific events occurs in the cells throughout the 
body under the influence of thyroid hormones. But the basic mechanisms 
leading to all these effects is still largely unknown. 
1) Effect on protein synthesis 
           Thyroid hormones increases the protein synthesis in almost all 
tissues of the body in experimental animals. 
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2) Effect on cellular enzyme systems 
           Thyroid hormones increases the level of more than 100 intra-
cellular enzymes. As an example, one enzyme, alpha-Glycerophosphate 
dehydrogenase can be increased to an activity six times of its normal level. 
3) Effect on mitochondria 
             Thyroid hormones increases the number and size of mitochondria 
in most cells of the body. 
4) Effect on cellular cyclic 
AMP 
             Thyroid hormones increases cyclic AMP in perhaps all cells of 
the body, especially so in muscle cells. Therefore, some believe that 
the primary action might be to activate adenylcyclase which in turn 
increases the formation of cyclic AMP. 
5) Effect on bone growth and calcium 
metabolism 
              Thyroid hormones increases the growth of bone. These 
hormones also cause rapid closure of epiphyses. Osteoclastic activity in 
the bones is increased. Greater than normal quantities of calcium and 
phosphate are excreted in the urine and gastrointestinal tract. 
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6) Effect on carbohydrate metabolism 
                  Thyroid hormones increases the uptake of glucose by all cells, 
glycolysis, gluconeogenesis and glucose absorption from gastro-intestinal 
tract. 
7) Effect on fat metabolism and vitamin 
metabolism 
                   All aspects of fat metabolism enhanced under the influence of 
thyroid hormones and also increased need for vitamins 
8) Effect on basal metabolic rate and body 
weight 
                   In   hyperthyroidism  basal  metabolic  rate   can   increase  
as   much  as 100 per cent above normal and decreases body weight 
despite increased appetite. On the other hand, when no thyroid hormone 
is produced, basal metabolic rate falls almost to one half the normal, 
that is the basal metabolic rate becomes 30 to 50 per cent. 
9) Effect on cardiovascular system 
                   The following effects occur in the cardiovascular system in 
hyper- thyroidism and the opposite effects occur in hypothyroidism. 
a) Increased blood flow and increased cardiac 
output. 
 b) Increase in the heart rate. 
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c) Slight increase in blood volume.  
d) Increase in pulse pressure. 
 
10) Effect on respiratory system 
        Thyroid hormones increase the rate and depth of respiration. 
 
11) Effect on gastrointestinal tract 
          Increase in absorption of products of digestion, motility of 
gastrointestinal tract and the appetite. 
12) Effect on central nervous system and sleep 
          Thyroid hormones increase the rapidity of cerebration. Thyroid 
hormone seem to increase synaptic activity but does not influence the 
peripheral nerve activity. Excess thyroid hormones cause difficulty in 
sleep. 
13) Effect on muscle 
           Excess of thyroid hormones cause the fine muscle tremors 10-15 
times per second. 
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2.14 Hypothyroidism: 
          Hypothyroidism is one of  the common problem encountered by both 
the sexes   women>men. The incidence of hypothyroidism in women found 
to be 350/10,0000 annually. The usual prevalence of subclinical 
hypothyroidism above 60 years females is found to be 20%. 
          Hypothyroidism is defined as decrease in the level of circulating 
thyroid hormones with increase in the level of circulating TSH. It may be 
due to pathology in hypothalamus, pituitary or thyroid gland itself. The rate 
of all metabolic process gets reduced. 
  Clinical symptoms : 
1) Hair loss 
2) Easy fatiguability 
3) Lethargy 
4) Memory disturbances 
5) Intolerance to cold 
6) Loss of appetite 
7) Increase in weight 
8) Hoarseness of voice 
9) Hearing impairment 
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10) Body pain 
11)  Constipation 
12) Menstrual irregularity 
 Clinical signs include: 
1)      Coarse and thin hair 
2)      Skin: dry and cold 
3)      Macroglossia 
4)      Slow speech 
5)      Anemia 
6)      Decrease in heart rate 
7)      Hypertension 
8)      Delayed deep tendon reflexes 
9)      Ascites 
10) Pleural and pericardial effusions 
11) Pedal edema 
12) vitiligo 
13)   In children, hypothyroidism leads to growth and mental 
retardation. 
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LAB FINDINGS:  
1) Increase in serum cholesterol level 
2) Anemia 
3) Clinical hypothyroidism: increased TSH; decreased free T3 and 
T4 with clinical features of hypothyroidism 
4) Subclinical hypothyroidism: increased TSH; Normal free T3 and 
T4 and the patient is mostly asymptomatic 
5) In case of hypothyroidism due to autoimmune thyroiditis, anti-
thyroperoxidase antibody may present.  
The treatment of hypothyroidism  is  Thyroxine supplementation. Mostly the 
hypothyroid patients need lifelong thyroxine supplementation. 
2.15 Prevalence of  Hypothyroidism in biliary stone patients: 
        For past years, several studies were conducted to report an correlation 
between hypothyroidism and gall stones.  
        A retrospective study conducted on 2001 (Inkinen et al.) on patients 
above 60 yrs of age.2 It was found that CBD stone patients had more 
prevalence of hypothyroidism (11%) when compared to non biliary stone 
patients (2%). They also compared the prevalence of hypothyroidism in Gall 
stones patients without CBD stone found to be 6%. They also found no 
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difference in the frequency of other diseases between these groups. This 
finding suggested the correlation between gall stones and hypothyroidism is 
not only due to alteration in cholesterol metabolism but also due to other 
factors like low bile flow in hypothyroidism. 
     A prospective study29 conducted in 2007 (Laukkarinen et al) showed that 
even subclinical hypothyroidism is more common in biliary stone disease. 
They studied the prevalence of subclinical hypothyroidism in clinically 
euthyroid biliary stone patients  and they compared with non biliary stone 
patients. Prevalence of subclinical hypothyroidism in biliary stone patients 
found to be 5.3% and in control patients found to be 1.4% . In more than 60 
yrs females, prevalence of subclinical hypothyroidism found to be 11.4% in 
biliary stone patients and in control patients it was found to be 1.8%. 
     In 2010, medical registry based large study conducted from finland 
(Laukkarinen et al)30 confirmed the relationship between gall stones and 
hypothyroidism. In this study, the prevalence of gall stones in hypothyroid 
patients compared with age, sex and area of residence adjusted glaucoma 
patients (control) were studied. Patients with other diseases were  excluded 
from the study. Out of 14,334 patients in each group, 23% in hypothyroid 
cohort and 16% in control cohort had treated for gall stones.  These groups 
did not differ statiscally in number of gall stone treatments. But 56% of gall 
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stone treated patients were found in hypothyroid cohort compared with 
glaucoma cohort. This suggest that stone formation may start during the 
untreated period of hypothyroidism. This hypothesis is supported by increased 
prevalence of both clinical and subclinical hypothyroidism in gall stone 
patients. 
TABLE 3: Results from various studies: 
STUDY YEAR NO. OF 
PATIENTS 
RESULTS 
Conducted in 
MCH 
Trivandrum 
2015 93 gall 
stone 
patients 
Sub clinical hypothyroidism present 
in 13%. Goiter present in 7.6% 
cases. Higher proportion of 
hypothyroidism with gall stones 
were noted in females (83.3%) 
compared with males (7.6%) 
P sundeshwari 
et al , GRH 
Madurai 
2014 200 gall 
stone 
patients 
18 patients had subclinical 
hypothyroidism and 6 patients had 
clinical hypothyroidism . 
prevalence of hypothyroidism in 
gall stones found to be 12% 
Conducted by 
Aishwin 
saravanakumar 
in Coimbatore 
2016 50 gall 
stone 
patients 
24% of gall stone patients had 
clinical/ subclinical hypothyroidism 
Conducted in 
PGIMS, Rohtak 
2017 200 gall 
stone 
patients 
10.5% had subclinical  
hypothyroidism and 3.5% had 
clinical hypothyroidism. Prevalence 
of hypothyroidism in gall stones 
found to be 14% 
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2.16 Mechanism   of    Formation   of   Gallstones   in   Hypothyroidism:   
          There are many factors that may account to the formation of biliary 
stones in hypothyroidism.  
In hypothyroidism, the decrease in 
the level of thyroxine 
➢ causes decrease in cholesterol metabolism31 leads to supersaturation of 
cholesterol in bile, which in decreases the motility, contractility and filling of 
gallbladder, which leads to  retention of cholesterol crystals  and formation of 
gall stones. 
➢ reduces the secretion of bile from liver resulting in  decreased clearance 
of precipitates from the biliary ducts.32 
➢decreases the sphincter of oddi relaxation leads to impaired bile flow. 
Stagnation of bile causes formation of stones33, 34, 35,36 
        Thyroid hormones act through interaction with their nuclear receptors 
which are expressed in a target tissue.37,38,39,40,41 In human, the Sphincter of 
oddi has both TR β1 and β2.  Actions of thyroid hormones  are  mostly 
intracellular  which  requires transport o f  t h y r o i d  h o r m o n e s  
across plasma membrane. Newly detected thyroid transporters are 
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monocarboxylate transporter 10 (MCT10), MCT8, and organic anion 
transporting polypeptide 1C1 (OATP1C1).42,43 
Hypothyroidism Reduces Bile Flow into the Duodenum: 
         In a study  conducted in rats, hypothyroidism causes sphincter of oddi 
contraction and decreased the rate of bile flow to duodenum whereas in  
hyperthyroidism  the bile flow was increased. Similarly, in a prospective study 
conducted in humans35,36, hepatic clearance of bile was significantly reduced  
and  bile flow  had  a  tendency  to decrease  in  the  hypothyroid  stage  after  
thyroidectomy,  when  compared  to  the euthyroid  stage  in  the  same  
patients.   In this study , the uptake of radioactivity in large bile ducts were 
found to be similar in both hypothyroid and euthyroid stages but in the 
hypothyroid stage the bile flow to duodenum is reduced. This is due to 
changes in composition of bile and hypomotility of gallbladder, and non 
relaxation of sphincter of oddi. 
Mechanisms by Which Thyroxine Mediates SO Relaxation: 
            The experiments studied using α- and β- receptor  blockers,  NO  
synthesis  blocker,  and  with tetrodotoxin ( eliminates the nerve function) 
proved that the thyroxine- induced relaxation of Sphincter of oddi is not 
mediated through neural effects. Human Sphincter of oddi has TR β1 and 
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β2. The presence of Thyroid receptors in sphincter of oddi34 is necessary 
but is no sufficient evidence that thyroid hormone exerts its prorelaxant 
effect through hormone-receptor ligand complex action. However, the 
experiments with thyroxine showed that the underlying cellular events  
require a certain time lag, which supports the theory that part of the action 
of thyroid hormone is TH-TR mediated. The binding of thyroxine with 
nuclear receptor is fast event, whereas the resulting transcription and 
translation  is time consuming, and this explains the not immediate 
relaxation of sphincter of oddi by thyroxine and this effect is mediated by 
regulatory proteins which are synthesized as a result of thyroxine-mediated 
gene expression. The prorelaxant effect of thyroxine is probably partly 
mediated via  partly via binding to nuclear receptors and partly via 
transporter proteins, subsequently leads to opening of  K+  channel results in 
hyperpolarisation, which closes the cell membrane Calcium channels, 
reduces Ca2+ influx, and results in decreased contraction of the Sphincter of 
oddi smooth-muscle cell.44,45,46 
2.17  Clinical Implications: 
               In summary, several recent studies “documented the association 
between hypothyroidism, or subclinical hypothyroidism, and biliary stones. 
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The higher prevalence of hypothyroidism in biliary stone patients compared 
to gallbladder stone patients suggests the reasons are not only due to changes 
in the cholesterol metabolism, or  decreased bile excretion rate,  but  
particularly alteration  in  the  function  of  sphincter of oddi  that  may  
account the correlation of gall stones and hypothyroidism. It remains to be 
investigated whether known hypothyroid patients whose gallbladder 
removed  for gall stones are at an higher risk to develop CBD stones when 
compared to normal euthyroid individuals or not.  The initial formation of 
bile cholesterol crystals may start during the undiagnosed/ untreated period of 
hypothyroidism, and the stones may continue to develop even after starting 
of  thyroxine replacement therapy. It is possible that thyroxine replacement 
therapy is not adequate in all patients to maintain  the normal Sphincter of 
oddi function, causing the increased risk of CBD stone formation. Studies 
shown that subclinical hypothyroid patients have alteration in the serum 
cholesterol level and prone to develop on cardiovascular disturbances, 
neuromuscular symptoms and this can be prevented by early replacement 
treatment with thyroxine, and it can be assumed that subclinical hypothyroid 
patients may also benefit from gall stone formation by early treatment with 
thyroxine. In conclusion patients who are presenting with gallstones, 
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especially females >40 years of age, may have subclinical hypothyroidism.  
S o ,  clinicians should  be  perform thyroid profile in all gall stone patients. 
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                              CHAPTER 3 
MATERIALS AND METHODS 
3.1 Type of study       : Cross- sectional study 
3.2  Study   approval  : Prior to commencement of this study - Thesis & 
Ethical Committee of Tirunelveli Medical College, Tirunelveli had 
approved the thesis protocol. 
3.3  Place of study      : Tirunelveli medical college Hospital 
3.4  Period of study   : Duration starting from December 2016 to August 
2018 
3.5  Sample size          : 100 cases 
3.6 Selection of patients: 
                  a) Sampling method- Purposive. 
                  b)Inclusion  criteria-  Patients  with  symptomatic  or  
asymptomatic cholelithiasis/ choledocholithiasis or both. 
                  c) Exclusion criteria - Patients with previous history of 
hypothyroidism on treatment 
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3.7 Investigations:    USG abdomen 
                                  Thyroid function test and USG thyroid 
                                    Lipid profile 
                                   CT abdomen if indicated 
                                   Liver function test 
3.8 Study procedure: 
                  Method  of  selecting cases  was  non-random,  purposive. After  
admission  clinical history was taken and physical examination was 
conducted on all patients who were admitted in General surgery department 
with features of Gall stone disease. Basic investigations were done, followed 
by imaging studies. About the disease nature and the possible line of 
management were explained to the patients. All the required information 
about this study was explained to the patients and their valid guardian. 
Informed written consent was taken from the patients and their guardian who 
are willing to participate in this study. Detailed history was obtained from the 
study group to establish proper diagnosis. Thorough physical examination 
was done in all cases. Data collection sheets were filled by the investigator 
himself. All of the preoperative factors related to the Gall stone disease were  
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noted  down  in  the  data  sheet. After  proper  evaluation  and pre-op 
preparation, patients  who  required  surgical  management  were  taken  up  
for  surgery.  Strict aseptic precautions were followed during surgery. 
Meticulous techniques were practiced . The surgery procedure and related 
peroperative factors were observed and recorded in the data collection sheet . 
After completing the collection of data it was compiled in a systematic way. 
Those who were found to be hypothyroid were started thyroxine 
supplementation therapy. 
3.9 Operational definitions: 
Cholelithiasis : presence of stones in gall bladder or CBD either single or 
multiple which are visualised by ultrasound abdomen/CT abdomen.  
Choledocholithiasis :  presence of stones in the common bile duct which 
are visualised by imaging methods. 
 Clinical Hypothyroidism : Decrease in level of circulating thyroid 
hormones with increased TSH. 
Sub-clinical Hypothyroidism: Normal T4 with slightly raised TSH.  
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Jaundice : Those with S. bilirubin > 1.2 mg/ dl were recorded as 
jaundiced. Hypercholestrolemia : an excess of cholesterol in the 
bloodstream. 
ERCP ( Endoscopic Retrograde CholangioPancreatography):  Procedure 
has both diagnostic and therapeutic value for pathology in the gallbladder, 
biliary system, pancreas, and liver. 
Types of operations: were recorded during each operation. 
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3.10Variables studied:  
i.   Age 
ii Sex 
iii. Co-morbidities 
iv. Lipid Profile 
v.  Ultrasonogram and CECT findings 
 vi. Thyroid function test 
vii. USG thyroid 
viii. Type of operation 
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3.10Ethical  consideration 
                 All the patients and legal guardians were given an explanation of 
this study and about the investigations and operative procedures with their 
own merits and demerits, expected results,  and  possible  complications.  If  
he/she  agreed, then  the case had been selected for this study. This study did 
not involve any additional investigation or any significant risk to the patient. 
It did not cause economic burden to the patients. The study was approved by 
the institutional ethical committee board prior to commencement of data 
collection. Informed consent was taken from all patients and their guardians.  
3.11 Data collection 
          Data were collected by pre-tested structured questionnaire. Data 
were collected from all the cases by direct interview after getting informed 
written consent from them and from their legal guardian. 
3.12 Data analysis 
         Data analysis was done both manually and by using computer. 
Calculated data were arranged in systemic manner, presented in various 
table and figures and statistical analysis was made to evaluate the 
objectives of this study with the help of Statistical Package for Social 
Science (SPSS). 
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CHAPTER  4 
RESULTS 
       This cross sectional study was carried out to determine the prevalence 
of hypothyroidism/ sub-clinical hypothyroidism among patients who 
admitted with either cholelithiasis or choledocholithiasis or both. One 
hundred patients fulfilling the inclusion criteria from Surgery department 
of Tirunelveli Medical College Hospital during the period of 
December2016 to August 2018 were selected. All cases were evaluated 
clinically. Only essential investigations necessary for diagnosis and 
preoperative assessment were done before operations. All patients 
underwent thyroid function test in addition. The patients of both sexes and 
different ages were included in this study. The results obtained are as 
follows. 
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TABLE 4: SEX DISTRIBUTION OF GALL STONE PATIENTS 
 SEX NO. OF PATIENTS PERCENTAGE 
MALE 27 27% 
FEMALE 73 73% 
TOTAL 100 Patients 100% 
 
 
MALE: FEMALE Sex Ratio: 1:2.7 
Gall stone disease found to be 2.7 times more common in females than 
males. 
  
MALE
27%
FEMALE
73%
SEX DISTRIBUTION
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TABLE 5: AGE DISTRIBUTION OF GALL STONE DISEASE: 
AGE GROUP IN YEARS MALE FEMALE 
20-29 4 7 
30-39 5 19 
40-49 9 28 
50-59 6 13 
>60 3 6 
Total 27 73 
 
Gall stones found to be most common in the age group of 40-49 years in 
both sexes. 
 
 
20-29 30-39 40-49 50-59 >60
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TABLE 6 CO-MORBIDITIS: 
CO-MORBIDITIS NO. OF PATIENTS 
Diabetes 8 
Hypertension 3 
Diabetes+ Hypertension 4 
Diabetes+ CAD 6 
Hypertension+ CAD 2 
Bronchial asthma 2 
Old PTB 1 
DM+ HTN+ CAD 1 
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TABLE 7 :USG ABDOMEN FINDINGS: 
USG abdomen findings No. Of patients 
Multiple GB calculi 67 
Single GB calculi 24 
GB+ CBD calculi 6 
CBD calculi 3 
TOTAL- 100 patients 
 
  
67%
24%
6% 3%
USG findings
multiple GB calculi single GB calculi GB+ CBD calculi CBD calculi
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TABLE 8. MANAGEMENT OF BILIARY STONES: 
PROCEDURE NO.OF PATIENTS 
Laparoscopic cholecystectomy 73 
Open/ lap converted open 
cholecystectomy 
18 
Open cholecystectomy + CBD 
exploration 
5 
ERCP 2 
ERCP+ Lap cholecystectomy 2 
 
In 100 gall stone patients, 21 patients were found to be hypothyroid. 4 
patients were males; 17 patients were females 
 
males
females
SEX DISTRIBUTION OF GALL STONES WITH 
HYOTHYROIDISM PATIENTS
MALES- 4 patients
FEMALES- 17 patients
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TABLE 9: AGE DISTRIBUTION OF PATIENTS WITH GALL 
STONES AND HYPOTHYROIDISM 
AGE GROUP IN 
YEARS 
MALE FEMALE 
20-29 0 0 
30-39 1 1 
40-49 2 9 
50-59 1 5 
>60 0 2 
TOTAL- 21 Patients 
 
 
 
20-29 30-39 40-49 50-59 >60
male 0 1 2 1 0
female 1 1 9 5 2
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TABLE 10: STATUS OF HYPOTHYROIDISM 
Thyroid status Male Female Total 
Sub-clinical 
hypothyroidism 
4 14 18 
Clinical hypothyroidism 0 3 7 
Total – 21 patients 
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TABLE 11: THYROID EXAMINATION ( CLINICAL+ USG 
THYROID) 
SEX GOITER WITHOUT GOITER 
Males Nil 4 
Females 5 12 
Total 5 17 
Among 21 hypothyroid patients, 5 patients had goiter, 17 patients were had  
clinically not enlarged thyroid gland. 
 
  
Thyroid examination
Normal thyroid gland
Goiter
GOITER- 5 
PATIENTS
NORMAL THYROID 
GLAND- 17 PATIENTS
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TABLE 12: FNAC OF GOITER 
FNAC REPORT NO. OF PATIENTS 
Colloid goiter 3 
Nodular goiter 2 
 
All hypothyroid patients were started with thyroxine supplementation 
  
82 
 
TABLE 13: SERUM CHOLESTEROL LEVEL AND GALL STONES 
SERUM 
CHOLESTEROL 
LEVEL IN mg/dl 
GALL STONES 
NO. OF PATIENTS 
GALL STONES+ 
HYPOTHYROIDISM 
<150 21 1 
150-200 34 6 
>200 45 14 
TOTAL 100 patients 21 patients 
 
  
<150mg/dl 150-
200mg/dl
>200mg/dl
GALL STONES+
HYPOTHYROIDISM
1 6 14
GALL STONES 21 34 45
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STONES
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TABLE 14: SERUM LDL LEVEL AND GALL STONES 
SERUM LDL 
LEVEL IN mg/dl 
No. of gall stone 
patients 
No. of gall stones with 
hypothyroidism 
patients 
<130mg/dl 17 2 
130-160 mg/dl 38 8 
>160mg/dl 45 11 
Total 100 patients 21 patients 
 
 
 
 
 
<130mg/dl 130-
160mg/dl
>160mg/dl
Gall stones +Hypothyroidism 2 8 11
Gall stones 17 38 45
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CHAPTER 5 
5.1 DISCUSSION: 
       This cross sectional study was conducted in 100 selected patients with 
either gall stones or CBD stones or both in Department of General surgery, 
Tirunelveli medical college. This study was carried out with a view to 
identify the prevalence of hypothyroidism in patients with extra hepatic 
biliary lithiasis in view of identifying its importance as a causative factor 
and to add the thyroid function test as a part of routine workup in biliary 
stone patients. 
      Most of the Gall stone patients were in the age group of 40-49 years.  
       Among this patients, 27%  were males; 73%  were females. 
       Male to female ratio: 1:2.7.  Females were the predominant group. 
       On analysing the co- morbid factors, Diabetes was the predominant 
co- morbidity associated with Gall stones. 
      On evaluation of patients with USG abdomen , 67% had multiple gall 
bladder calculi, 24% had single gall bladder calculi, 6% had both gall 
bladder and CBD calculi, 3% had CBD calculi. 
     Patients were managed with both laparoscopic and open procedures. 73 
patients underwent laparoscopic cholecystectomy, 18 patients were treated 
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with open/ lap converted open cholecystectomy. The reason for conversion 
of laparoscopic to open procedure were adhesions, bleeding and technical 
issues. 4 patients of  both gall bladder and CBD calculi  and 1 patient of 
CBD calculi underwent open cholecystectomy with CBD exploration. 2 
patients of both gall bladder and CBD calculi underwent ERCP+ 
laparoscopic cholecystectomy. 2 patients of CBD calculi treated with 
ERCP. 
    In 100 gall stone patients , 21 patients were found to be hypothyroid 
(21%).79 patients (79%)  found to be Euthyroid. 
    Among 21 hypothyroid patients,  4 patients (4%) were males and 17 
patients (17%) were females.  
    Most of gall stone patients with hypothyroidism were found to be in the 
age group of  40-49 years of age. 
    18 patients (18%) had subclinical hypothyroidism and gall stones. 3 
patients (3%) had clinical hypothyroidism).  
    Thyroid examination by clinical and USG examination showed 5 
patients had goiter. Others had no clinically enlarged thyroid gland. 
    FNAC done for that 5 goiter patients showed 3 had colloid goiter and 2 
had nodular goiter. 
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   All hypothyroid patients were started with thyroxine supplementation 
therapy ( T. Thyroxine 100 microgram OD in empty stomach). 
    Most of gall stone patients (45%)  had raised serum cholesterol and LDL 
level. 
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5.2 LIMITATIONS OF THE STUDY: 
1) Small sample size. 
2) Assessment of composition of gall stones not done. 
3) Assessment of mobility of biliary tract not done to demonstrate 
decreased rate of  bile flow in hypothyroid patients. 
Eventhough this study has some limitations, it has some credentials in 
reflecting the facts regarding prevalence of hypothyroidism in gall stone 
patients and its positive correlation with gall stone disease. 
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5.3 RECOMMENDATION 
   The recommendation made from this study is Evaluation of thyroid 
function test  should be a part of general workup in patients with biliary 
stone disease especially in female patients 
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CHAPTER 6 CONCLUSION 
       This cross sectional study was conducted in Department of General 
surgery, Tirunelveli medical college hospital. It can be concluded from the 
findings of this study that hypothyroidism is a probable risk factor for 
development of Gall stones especially in middle aged females. Undetected 
and untreated hypothyroidism in such patients will result in complications. 
Clinicians should be aware of possible hypothyroid background and 
consider examining the thyroid profile atleast in females over 40 years of 
age, in which group the prevalence of clinical and sub clinical 
hypothyroidism is the highest. 
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DATA COLECTION CHART 
QUESTIONAIRE 
Patient details: 
Name: 
Age:                                           
sex: 
IP No. 
ON ADMISSION: 
Main Complaints                                   : 
Symptoms of Gallstone/CBD stones      
H/o right upper quadrant pain                : 
H/o vomiting                                             : 
H/o dyspepsia                                            :  
H/o fever                                                  : 
H/o jaundice                                           : 
Symptoms of Hypothyroidism                
 H/o weight gain                                        :  
H/o weakness/ lethargy                             : 
H/o intolerance to cold                            : 
H/o constipation                                   :  
H/o swelling of face or limbs               :  
H/o loss of hair / dry skin                     :  
Co – Morbid Illness                              : 
 Significant Past History                       : 
CLINICAL EXAMINATION: 
Pulse:                                     BP:                            RR:                       Temp: 
 Pallor:                                     Icterus: 
CVS:                                       RS: 
P/A: 
Thyroid examination: 
INVESTIGATIONS: 
 Hemogram:                                                
Renal Function Test:  
Liver Function Test: 
BT/CT:                                   Blood Grouping:           Fasting Lipid Profile: 
 ECG:                                     CXR: 
USG Abdomen:                       CT Abdomen: 
  USG Thyroid:                         FNAC Goiter: 
Thyroid profile: T3 --                        T4 --                   TSH — 
Operative Procedure: 
FOLLOW UP: 
 
Lipid profile
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ce
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appetite/ 
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gain
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pation
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nces
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T4 
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/dl
TSH 
(micro 
IU/ml)
GB 
Calculi
CBD 
Calculi
No. Of 
Calculi
FNAC
THYROID 
MANAGE
MENT
1 PEER AVULIYA 52 M 63457 - - + - - DM N 1 0.3 225/185/165/34 1.6 7.2 0.6 + - multiple lap chol Euthyroid
2 MARI 25 F 67423 - - - - - NIL N 0.9 0.2 142/168/145/46 0.8 4.9 1 + - single lap chol Euthyroid
3 PETCHI AMMAL 44 F 66534 - + - + - DM N 4.8 3.6 173/163/155/42 0.7 5.1 16.3 + + multiple open chol/ CBD exp subclinical hypothyroid Thyroxine
4 MADASAMY 33 M 67458 - - - - - NIL N 1.2 0.4 165/155/145/40 0.7 5.2 4.8 + - multiple lap chol Euthyroid
5 NAKOORAMMAL 66 F 69865 - - - - - NIL N 1.2 0.3 253/165/172/42 1.3 7 0.9 + - multiple open chol Euthyroid
6 CHELLAMMAL 43 F 67547 - - - - + NIL N 6.3 4.9 192/165/152/41 1.9 8.6 4 - + single ERCP Euthyroid
7 ANANTHAN 27 M 70987 - + - - - NIL N 0.9 0.3 135/115/120/45 0.6 5.2 1.2 + - multiple lap chol Euthyroid
8 VELLATHAI 58 F 71267 - - - - - DM+HTN N 0.8 0.2 234/167/178/42 1.6 6.5 0.8 + - multiple lap chol Euthyroid
9 BHUVANESWARI 28 F 72341 - - - - - NIL N 1.2 0.2 135/160/126/51 1.3 5.1 0.7 + - single lap chol Euthyroid
10 BALA ARASI 44 F 74532 - + - - + NIL Goiter 1 0.2 167/150/145/51 0.7 4.9 14.4 + - multiple lap chol subclinical hypothyroid colloid goiter Thyroxine
11 MUPPIDATHY 46 F 79865 - - - - - OLD PTB N 1.2 0.4 138/154/142/43 1.3 4.4 0.6 + - multiple lap chol Euthyroid
12 KOTHAI AMMAL 56 F 124 - + - + - NIL N 0.9 0.2 289/167/170/40 1.5 5.1 0.8 + - single lap chol Euthyroid
13 MUTHU VINAYAGAM 48 M 678 - + + - - HTN N 0.9 0.4 168/155/145/45 0.6 4.9 18.6 + - multiple lap chol subclinical hypothyroid Thyroxine
14 CHITRA 35 F 1267 - - - - + NIL N 1.3 0.3 159/126/138/52 1.6 7.8 2.2 + - single lap chol Euthyroid
15 ANNAI AMMAL 54 F 1543 - - - - - NIL N 1.2 0.3 234/175/185/38 1.9 8.2 0.8 + - multiple lap chol Euthyroid
16 SELVI 34 F 1784 - - - - - NIL N 1 0.2 162/137/141/48 1 5.2 1.4 + - multiple open chol Euthyroid
17 MOOKANDI 35 M 1985 - - - - - NIL N 5.7 4.2 175/145/135/45 0.9 5.1 17.2 + + multiple open chol/ CBD exp subclinical hypothyroid Thyroxine
18 CHELLAMMAL 56 F 10965 - - - - - DM N 0.9 0.2 253/156/178/42 1.5 7 0.8 + - multiple lap chol Euthyroid
19 AYYAR 58 M 10764 - + - - - DM+OLD CAD N 0.9 0.3 220/195/145/35 0.7 5.2 20.3 + - single lap chol subclinical hypothyroid Thyroxine
20 JOTHI 35 F 10342 - - - - + NIL N 1.2 0.3 195/154/168/42 1.8 7.2 0.9 + - multiple lap chol Euthyroid
21 RAHAMATH NISHA 29 F 11432 - - - - - NIL N 1 0.2 142/134/121/52 1.6 6.7 1.4 + - multiple lap chol Euthyroid
22 ANAND MUTHURAJ 28 M 11763 - - - - - NIL N 1.2 0.2 125/135/135/40 1.8 5.6 5.3 + - single lap chol Euthyroid
23 MALAI APPAN 44 M 11343 - + + - - DM N 0.8 0.2 225/195/170/45 0.9 7.2 2.4 + - multiple lap chol Euthyroid
24 SERMAKANI 32 F 12653 - - - - - NIL N 0.8 0.3 154/123/142/56 0.7 6 2.1 + - multiple lap chol Euthyroid
25 VELAMMAL 65 F 11232 - - - - - DM N 1 0.2 309/195/198/35 0.9 5.1 0.9 + - multiple lap chol Euthyroid
26 LAKSHMI 37 F 12897 - - + - - NIL N 1.1 0.3 213/154/165/48 1.4 7.1 0.7 + - single open chol Euthyroid
27 SARASWATHI 43 F 14563 - + - - - DM N 1.2 0.4 165/154/148/52 1.1 10.2 0.6 + - multiple lap chol Euthyroid
28 BALA AMMAL 53 F 14897 + + - + - NIL Goiter 1.1 0.2 231/195/178/53 0.2 4 20.2 + - multiple open chol Hypothyroid nodular goiter thyroxine
29 MUTHU AMMAL 63 F 14325 - - - - - NIL N 0.9 0.2 245/179/165/41 1.6 7.9 0.6 + - multiple lap chol Euthyroid
30 KAVI PRIYA 35 F 15764 - - - - + NIL N 0.8 0.2 135/143/142/43 1.2 8.9 0.7 + - multiple lap chol Euthyroid
31 MARIYA PREMA 47 F 15098 - - - - - NIL N 0.9 0.3 174/155/138/49 1.1 6.4 0.9 + - Single lap chol Euthyroid
32 THANGAMMAL 52 F 16097 - + - - - BA N 5.1 3.8 216/186/174/42 1.2 5.9 0.8 - + Single CBD expl Euthyroid
33 KUMAR 36 M 16532 - - - - - NIL N 1.2 0.3 135/115/125/45 0.6 5.1 0.7 + - multiple lap chol Euthyroid
34 POONKODI 37 F 17865 - - - - - NIL N 1.1 0.2 165/145/149/51 1.2 5.2 0.9 + - multiple lap chol Euthyroid
35 PARVATHI 42 F 18436 - + - - - NIL N 1.2 0.4 254/178/187/37 1.6 7.2 0.7 + - multiple open chol Euthyroid
36 SELVI 41 F 18321 - - - - - NIL N 1 0.2 168/143/146/48 1.1 5.2 4.8 + - multiple lap chol Euthyroid
37 RAMASAMY 64 M 19087 - - - - - DM+OLD CAD N 1.1 0.2 245/195/170/41 1.2 8.3 2.4 + - single open chol Euthyroid
38 NAZEER BEGAM 54 F 21157 - + - - - NIL N 1.2 0.3 265/176/196/36 0.8 5 19.4 + - multiple lap chol subclinical hypothyroid thyroxine
39 INDIRA 33 F 21455 - - - - - NIL N 6.7 4.8 155/165/143/57 1.3 7.3 4.2 + + multiple open chol/ CBD exp Euthyroid
40 LAKSHMI 27 F 21897 - - - - - NIL N 1.1 0.3 132/154/126/52 1.4 6.5 2.3 + - multiple open chol Euthyroid
41 PADMAVATHI 32 F 24656 - + - - - NIL N 1.2 0.2 135/126/122/45 0.6 4.9 18.3 + - single lap chol subclinical hypothyroid thyroxine
42 MUTHUAMMAL 42 F 25432 - - - - - NIL N 1.1 0.2 168/154/142/51 1.1 6.1 0.9 + - multiple lap chol Euthyroid
43 MARIMUTHU 42 M 26789 - - - - - NIL N 1.2 0.3 155/160/155/45 1.3 6.7 2.6 + - multiple lap chol Euthyroid
44 THANGARAJ 47 M 26908 - - - - - DM+HTN N 1.2 0.3 165/150/145/43 1.5 5.9 3.2 + - multiple open chol Euthyroid
45 AYYAPAN 62 M 26743 - + - + - DM+OLD CAD N 0.9 0.2 225/195/190/33 1.6 5.1 2.2 + - multiple lap chol Euthyroid
46 NELLAI VADIVU 43 F 27805 - - - - - NIL N 0.9 0.2 225/176/178/39 1.2 6.3 4.3 + - multiple lap chol Euthyroid
47 SUBBAMMAL 45 F 27604 - - - - - NIL N 0.9 0.2 234/186/174/40 1.4 5.7 3.6 + - multiple lap chol Euthyroid
48 PERACHI 36 F 28904 - - - - - NIL N 1.2 0.2 165/142/148/46 1.3 6.7 4.1 + - single open chol Euthyroid
49 THANGA PUSPAM 46 F 28643 - - - - - NIL N 1.1 0.3 223/165/168/43 1.5 8.1 0.9 + - multiple lap chol Euthyroid
50 KUMAR 46 M 28621 - - + + - NIL N 1.2 0.3 173/165/145/48 0.9 4.7 20.1 + - multiple lap chol subclinical hypothyroid thyroxine
51 RAJA AMMAL 43 F 29046 - - - - - NIL N 0.9 0.2 224/178/189/42 1.2 7.3 0.8 + - multiple open chol Euthyroid
52 TAMIL SELVI 34 F 30097 - - - - - NIL N 0.9 0.2 231/187/181/40 1.6 6.9 3.7 + - multiple lap chol Euthyroid
53 NALLA KANNU 53 M 31157 - + - - - HTN+OLD CAD N 1.4 0.3 315/195/190/38 1.2 8.2 4.3 + - single lap chol Euthyroid
54 MARIAMMAL 56 F 32114 - - - + - DM+OLD CAD N 1.2 0.2 297/197/210/32 0.6 5.1 19.2 + - multiple open chol subclinical hypothyroid thyroxine
55 LAKSHMI 27 F 32565 - - - - - NIL N 0.9 0.2 165/145/147/49 1.1 5.6 4.9 + - multiple lap chol Euthyroid
56 LATHA 43 F 32678 - - - - - NIL N 1.1 0.3 172/183/143/51 0.9 6.2 2.1 + - multiple lap chol Euthyroid
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57 MURUGAN 45 M 32656 - - - - - NIL N 1.2 0.4 165/155/140/43 1.7 5.8 3.7 + - multiple lap chol Euthyroid
58 JEYALAKSHMI 46 F 33354 + + - + - NIL Goiter 1.4 0.4 223/192/174/42 0.3 2.1 23.1 + - multiple lap chol Hypothyroid colloid goiterthyroxine
59 MUTHU SELVI 47 F 33453 - - - - - NIL N 0.9 0.2 212/156/165/48 1.6 7.3 5.6 + - single lap chol Euthyroid
60 MAHA LAKSHMI 38 F 32334 - - - - - NIL N 1.1 0.2 132/112/117/52 1.8 5.8 4.6 + - multiple lap chol Euthyroid
61 VIJAYA 42 F 34548 - - - + + NIL N 5.7 3.8 174/156/152/49 0.7 5.1 16.7 + + multiple ERCP+lap chol subclinical hypothyroid thyroxine
62 VADIVU 56 F 34212 - - - - - DM N 0.9 0.2 154/136/142/52 1.2 7.6 2.3 + - multiple lap chol Euthyroid
63 MUTHUSAMY 38 M 35427 - - - - - NIL N 0.9 0.2 258/195/173/42 1.1 6.7 3.4 + - single open chol Euthyroid
64 RAJESHWARI 37 F 35765 - - - - - NIL N 1.2 0.2 135/156/120/52 1.4 7.3 2.5 + - single lap chol Euthyroid
65 BALAN 52 M 35763 - - - - - HTN+OLD CAD N 1.2 0.3 315/203/194/37 1.2 6.8 4.1 + - multiple lap chol Euthyroid
66 PETCHI 53 F 36753 - + - + - HTN N 1.1 0.2 224/165/168/47 0.2 2.7 19.8 + - multiple lap chol Hypothyroid thyroxine
67 PREMA 41 F 37545 - - - - - NIL N 1.1 0.2 141/126/126/51 0.9 5.6 0.9 + - multiple lap chol Euthyroid
68 ROHINI 46 F 36542 - - - - - NIL N 1.1 0.3 234/156/168/48 1.4 6.9 3.1 + - single open chol Euthyroid
69 SORNAKANI 32 F 35753 - - - - - NIL N 1.3 0.4 183/154/148/48 1.6 7.3 2.1 + - multiple lap chol Euthyroid
70 MANI RAJ 37 M 36752 - - - - - NIL N 0.9 0.2 264/195/188/37 0.9 5.6 2.1 + - multiple lap chol subclinical hypothyroid thyroxine
71 VELAMMAL 66 F 37314 - + + - - NIL N 0.9 0.3 163/145/151/47 0.8 5.1 14.4 + - single lap chol subclinical hypothyroid thyroxine
72 ANTHONY 28 M 38976 - - - - - NIL N 1.1 0.3 131/123/115/49 1.1 5.3 3.1 + - multiple lap chol Euthyroid
73 CHINNA PONNU 28 F 30976 - - - - + NIL N 7.8 5.2 142/135/121/52 1.1 6.7 2.1 + + multiple open chol/CBD exp Euthyroid
74 MYDEEN BEEVI 46 F 31232 - - - - - BA N 0.9 0.3 245/187/195/45 0.6 4.8 16.3 + - single open chol subclinical hypothyroid thyroxine
75 ULAGAMMAL 57 F 37897 - - - - - NIL N 1.1 0.3 165/154/143/49 1.6 7.2 0.8 + - multiple lap chol Euthyroid
76 MARIYAPPAN 64 M 38764 - - - - - NIL N 0.9 0.2 235/197/205/36 1.1 5.3 3.1 + - single lap chol Euthyroid
77 VALLI 42 F 38097 - + - + - DM+HTN N 0.9 0.3 298/195/187/40 1.3 6.1 4.1 + - multiple lap chol Euthyroid
78 RAJESHWARI 31 F 28124 - - - - - NIL N 1 0.2 132/142/112/52 1.1 5.7 2.1 + - multiple open chol Euthyroid
79 JEYA SUDHA 43 F 38342 - - - + - NIL N 0.9 0.2 155/158/149/44 0.5 4.6 18.2 + - multiple lap chol subclinical hypothyroid thyroxine
80 MEENATCHI 53 F 32135 - - - - - DM N 1.1 0.2 278/165/175/45 1.2 6.3 2.7 + - single lap chol Euthyroid
81 SANKARA LINGAM 56 M 38976 - - + - - NIL N 8.1 6.7 215/155/195/37 0.9 5.6 1.2 - + single ERCP Euthyroid
82 MUTHU SELVI 47 F 38654 - + - - - NIL N 1.1 0.3 267/185/176/37 0.9 6.2 3.1 + - multiple lap chol Euthyroid
83 ESAKKI AMMAL 35 F 39087 - - - - - NIL N 1.2 0.4 138/150/121/52 1.1 7.6 3.7 + - multiple lap chol Euthyroid
84 SHANTHI 46 F 39867 - - - - - NIL N 1.2 0.3 165/154/141/42 1.4 7.2 0.9 + - single lap chol Euthyroid
85 AMBIKA 42 F 39125 - + - - + NIL Goiter 1.4 0.4 265/186/178/41 1.1 5.2 15.6 + - multiple lap chol subclinical hypothyroid nodular goiter thyroxine
86 SHEIK MOHAMED 52 M 40005 - - - - - DM+HTN N 1.2 0.3 256/175/172/44 1.4 6.9 2.1 + - multiple open chol Euthyroid
87 VEERA AMMAL 65 F 40012 - + - - - DM+OLD CAD N 1.1 0.4 298/165/176/43 1.1 5.2 16.1 + - single lap chol subclinical hypothyroid thyroxine
88 UTHRA 43 F 40564 - - - - - HTN N 1.2 0.2 135/143/121/52 1.3 6.2 4.6 + - multiple lap chol Euthyroid
89 PON MARI 36 F 40521 - - - - - NIL N 1.2 0.3 165/171/142/47 1.2 6.7 4.3 + - multiple lap chol Euthyroid
90 GANESAN 46 M 40653 - - - - - NIL N 1.3 0.4 223/169/184/42 1.1 5.8 3.4 + - single lap chol Euthyroid
91 KANAGA RAJ 42 M 40123 - - - - - NIL N 1.1 0.2 256/188/176/43 1.6 5.2 1.8 + - single lap chol Euthyroid
92 SHANMUGA VADIVU 48 F 40234 - - - + - NIL N 0.9 0.2 194/174/153/45 0.9 4.6 16.1 + - multiple lap chol subclinical hypothyroid thyroxine
93 BAKKERAL BANU 63 F 40432 - - + - - DM+HTN+CAD N 0.9 0.2 314/237/216/30 1.2 5.8 2.1 + - multiple open chol Euthyroid
94 SARASWATHI 32 F 40657 - - + - - NIL N 1.2 0.3 214/160/164/45 1.4 6.7 2.3 + - multiple lap chol Euthyroid
95 KARPAGA VALLI 48 F 40784 - + - + - NIL Goiter 9.3 6.7 135/159/115/45 1.2 5.1 16.7 + + multiple ERCP+lap chol subclinical hypothyroid colloid goiterthyroxine
96 XAVIER 44 M 41238 - - - - - NIL N 0.9 0.2 165/155/140/42 0.9 5.2 2.1 + - single lap chol Euthyroid
97 PARAMESHWARI 26 F 41234 - - + - - NIL N 0.9 0.3 145/115/124/55 1.4 5.7 1.2 + - multiple lap chol Euthyroid
98 KARUNAKARAN 26 M 41543 - - - - - NIL N 1.3 0.4 132/115/100/50 1.5 6.7 0.9 + - multiple open chol Euthyroid
99 ARPUTHA MARY 54 F 41532 - + - + - DM+OLD CAD N 1.2 0.3 215/176/168/48 0.6 4.9 15.5 + - multiple lap chol subclinical hypothyroid thyroxine
100 SORNA KILI 34 F 41674 - - - - - NIL N 0.9 0.2 165/145/143/48 0.9 5.6 6.8 + - multiple lap chol Euthyroid
DM DIABETES MELLITUS 
HTN HYPERTENSION 
OLD PTB OLD PULMONARY TUBERCULOSIS 
CAD CORONARY ARTERY DISEASE 
BA BRONCHIAL ASTHMA 
CHOL SERUM CHOLESTEROL 
TGL SERUM TRIGLYCERIDE 
LDL LOW DENSITY LIPOPROTEIN 
HDL HIGH DENSITY LIPOPROTEIN 
LAP 
CHOL 
LAP CHOLECYSTECTOMY 
OPEN 
CHOL 
LAP CONVERTED OPEN/OPEN CHOLECYSTECTOMY 
T3 REF RANGE: 0.5-2.0 ng/ml 
T4 REF RANGE: 4.4-11.6 microgm/dl 
TSH REF RANGE: 0.5-7.0 microIU/ml 
 
